Comparing Revenue Performance: Jazz Pharmaceuticals plc or Bausch Health Companies Inc.?

Pharma Revenue Race: Jazz vs. Bausch

__timestampBausch Health Companies Inc.Jazz Pharmaceuticals plc
Wednesday, January 1, 201482635000001172875000
Thursday, January 1, 2015104988000001324803000
Friday, January 1, 201696740000001487973000
Sunday, January 1, 201787240000001618693000
Monday, January 1, 201883800000001890922000
Tuesday, January 1, 201986010000002161761000
Wednesday, January 1, 202080270000002363567000
Friday, January 1, 202184340000003094238000
Saturday, January 1, 202281240000003659374000
Sunday, January 1, 202387570000003834204000
Loading chart...

Unleashing insights

Revenue Trends: Jazz Pharmaceuticals vs. Bausch Health

In the competitive landscape of pharmaceuticals, revenue growth is a key indicator of success. From 2014 to 2023, Jazz Pharmaceuticals plc has shown a remarkable upward trajectory, with revenue increasing by over 225%. Starting at approximately $1.17 billion in 2014, Jazz Pharmaceuticals reached nearly $3.83 billion by 2023. This growth reflects a strategic expansion and successful product launches.

Conversely, Bausch Health Companies Inc. experienced a more fluctuating revenue pattern. Despite a peak in 2015, with revenues reaching around $10.5 billion, the company saw a decline, stabilizing around $8.76 billion in 2023. This represents a 16% decrease from its peak, highlighting challenges in maintaining consistent growth.

These trends underscore the dynamic nature of the pharmaceutical industry, where innovation and market adaptation are crucial for sustained success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025